Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation

Eveline van Gurp, Jesús Bustamante, Antonio Franco, Lionel Rostaing, Thomas Becker, Éric Rondeau, Z Czajkowski, Andrzej Rydzewski, Antonio Alarcón, Petr Bachleda, J Samlík, Dirk Burmeister, Luis Pallardó, Marie‐Christine Moal, Leszek Rutkowski, Zbigniew WłodarczykJournal of Transplantation 2010 · DOI

TL;DR

This multicenter randomized trial found that combining tacrolimus with either sirolimus or mycophenolate mofetil (MMF) resulted in comparable renal function at 6 months post-transplant. While both regimens offered similar graft and patient survival, the sirolimus combination led to more adverse events like hypercholesterolemia and higher rates of premature withdrawal, suggesting MMF might be a more tolerable alternative for some patients.

What Problem Does This Paper Address?

Following a kidney transplant, patients require immunosuppressive drugs to prevent their new kidney from being rejected by their immune system. Tacrolimus is a cornerstone of these regimens, but it's often combined with other drugs to enhance its effectiveness and manage potential side effects. Two common combinations are tacrolimus with sirolimus (Tac/SRL) and tacrolimus with mycophenolate mofetil (Tac/MMF). While both are effective, there's ongoing debate about their comparative efficacy, particularly regarding renal function preservation, and their safety profiles. Specifically, concerns exist about sirolimus potentially exacerbating tacrolimus-induced nephrotoxicity (kidney damage), while MMF has its own set of side effects. This study aimed to directly compare these two regimens in a large, multicenter setting to determine if one offered superior renal function and to thoroughly assess their safety and tolerability.

Methods

This was a prospective, randomized, multicenter, phase III clinical trial involving 51 centers across 13 European countries. Adult patients (18-60 years old) undergoing primary renal transplantation or retransplantation were randomized in a 1:1 ratio to receive either:

  • Tacrolimus/Sirolimus (Tac/SRL): Tacrolimus was administered with a fixed-dose sirolimus regimen. Notably, targeted tacrolimus trough levels were intentionally set lower after day 14 in the Tac/SRL group to mitigate potential nephrotoxicity.
  • Tacrolimus/Mycophenolate Mofetil (Tac/MMF): Tacrolimus was combined with MMF.

The primary endpoint was renal function at 6 months, assessed using the Cockcroft-Gault formula for creatinine clearance. Secondary endpoints included biopsy-confirmed acute rejection (BCAR), patient and graft survival, and the incidence of adverse events. Statistical analysis focused on comparing the mean creatinine clearance between groups, with a predefined margin for non-inferiority.

Datasets

Not discussed in the paper. The study involved data collected from patients enrolled in the clinical trial.

Key Insights and Ideas

  • Non-inferiority Confirmed: The study successfully demonstrated that the Tac/SRL regimen is non-inferior to the Tac/MMF regimen in terms of preserving renal function at 6 months post-transplant. This is a crucial finding for clinicians deciding on immunosuppressive strategies.
  • Dosing Strategy Matters: The researchers implemented a novel fixed-dose sirolimus strategy and adjusted tacrolimus trough levels, particularly lowering them in the Tac/SRL group after the initial post-operative period. This approach likely contributed to the comparable renal function observed, potentially mitigating some of the previously reported nephrotoxicity concerns with sirolimus.
  • Tolerability Trade-offs: While renal function was similar, the safety profiles differed. The Tac/SRL group experienced a higher incidence of hypercholesterolemia and a significantly higher rate of premature withdrawal due to adverse events. Conversely, the Tac/MMF group saw more instances of CMV infection, leukopenia, and diarrhea. This highlights that the choice of regimen involves a trade-off between different types of adverse events.
  • Steroid Withdrawal Challenges: Adherence to protocol-defined steroid withdrawal was suboptimal in both groups, with a significant portion of patients still on steroids at later time points. This suggests that achieving steroid-free immunosuppression remains a clinical challenge.

Key Results

  • Renal Function: At 6 months, mean creatinine clearance was comparable between groups: 66.4 mL/min (SE 1.4) for Tac/SRL and 65.2 mL/min (SE 1.3) for Tac/MMF (among completers).
  • Acute Rejection: Biopsy-confirmed acute rejection (BCAR) rates were similar, with 15.1% in the Tac/SRL group and 12.3% in the Tac/MMF group.
  • Survival: Graft survival at 6 months was 92.7% for Tac/SRL and 93.3% for Tac/MMF. Patient survival was high in both groups, at 99.0%.
  • Adverse Events:
    • Premature withdrawal due to adverse events was twice as high in the Tac/SRL group (15.1%) compared to the Tac/MMF group (6.3%).
  • Hypercholesterolemia was more frequent with Tac/SRL (P < .05).
  • CMV infection, leukopenia, and diarrhea were more frequent with Tac/MMF (P < .05, and P < .001 for CMV and leukopenia).
  • De novo diabetes mellitus incidence was lower with Tac/SRL (17.8%) compared to Tac/MMF (24.8%).

Limitations and Future Work

  • Study Duration: The 6-month duration of the study limits the ability to project long-term renal function or graft survival. The authors acknowledge that longer follow-up is needed to fully assess the long-term benefits and risks of each regimen.
  • Steroid Withdrawal: The low adherence to steroid withdrawal protocols means that the study cannot definitively comment on the safety of early steroid withdrawal at 3 months.
  • Imputation of Missing Data: While a sensitivity analysis was performed on patients with available data at 6 months, the authors note that an analysis using imputation for missing data might provide additional insights, though they suspect it wouldn't alter the primary conclusion.
  • Future Directions: The study design makes it difficult to pinpoint specific variables that might mitigate or accelerate nephrotoxicity. Future research could focus on identifying such factors and exploring longer-term outcomes and the impact of different dosing strategies. The authors also suggest that further investigation into the feasibility of fixed-dose sirolimus reduction schemas without compromising efficacy is warranted.

Summary updated

Abstract

In a multicenter trial, renal transplant recipients were randomized to tacrolimus with fixed-dose sirolimus (Tac/SRL, N = 318) or tacrolimus with MMF (Tac/MMF, N = 316). Targeted tacrolimus trough levels were lower in the Tac/SRL group after day 14. The primary endpoint was renal function at 6 months using creatinine clearance (Cockcroft-Gault) and was comparable at 66.4 mL/min (SE 1.4) with Tac/SRL and at 65.2mL/min (SE 1.3) with Tac/MMF (completers). Biopsy-confirmed acute rejection was 15.1% (Tac/SRL) and 12.3% (Tac/MMF). In both groups, graft survival was 93% and patient survival was 99.0%. Premature withdrawal due to an adverse event was twice as high in the Tac/SRL group, 15.1% versus 6.3%. Hypercholesterolemia incidence was higher with Tac/SRL (P < .05) while CMV, leukopenia, and diarrhea incidences were higher with Tac/MMF (P < .05). The incidence of any antidiabetic treatment for >30 consecutive days in previously nondiabetic patients was 17.8%, Tac/SRL, and 24.8%, Tac/MMF. Evaluation at 6 months showed comparable renal function using tacrolimus/sirolimus and tacrolimus/MMF regimens.
BibTeX
@article{gurp2010comparable,
  author = {Eveline van Gurp and Jesús Bustamante and Antonio Franco and Lionel Rostaing and Thomas Becker and Éric Rondeau and Z Czajkowski and Andrzej Rydzewski and Antonio Alarcón and Petr Bachleda and J Samlík and Dirk Burmeister and Luis Pallardó and Marie‐Christine Moal and Leszek Rutkowski and Zbigniew Włodarczyk},
  title = {{Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation}},
  journal = {Journal of Transplantation},
  year = {2010},
  doi = {10.1155/2010/731426},
}
Figure